Complement activation by pulsed tunable dye laser in normal skin and hemangioma.
Pulsed tunable dye laser (577 nm) (PTDL) therapy induces hemoglobin coagulation and tissue necrosis, which is mainly limited to blood vessels. To define whether this treatment activates complement in normal skin and senile hemangioma, we analyzed complement deposition in blood vessels by immunofluorescence. C3 fragments, C8, and C9 were detected with specific polyclonal antibodies. The membrane attack complex of complement (MAC) was demonstrated with a monoclonal antibody which reacts only with a neoantigen of MAC. Amplification of C3 deposition by the alternative pathway was determined on cryostat sections by indirect immunofluorescence with use of C4 deficient guinea pig (GP) serum. Normal skin and hemangiomas from three individuals were studied. In PTLD-irradiated normal skin, the main findings were as follows: 1) C3 fragments, C8, C9, and MAC were deposited in vessel walls; 2) these deposits were not due to denaturation of the proteins since they became apparent only 7 min after irradiation, contrary to immediate deposition of transferrin at the sites of erythrocyte coagulates; 3) the C3 deposits were shown to amplify complement activation by the alternative pathway, a reaction which was specific since tissue necrosis itself did not lead to such amplification; 4) these reactions preceded the local accumulation of polymorphonuclear leucocytes. Tissue necrosis was more pronounced in the hemangiomas. The larger angiomatous vessels in the center of the necrosis did not fix complement significantly. By contrast, complement deposition in the vessels situated at the periphery was similar to that observed in normal skin with one exception: C8, C9, and MAC were detected in some blood vessels immediately after laser treatment, a finding consistent with assembly of the MAC occurring directly without the formation of a C5 convertase. These results indicate that complement is activated in PTDL-induced vascular necrosis, and might be responsible for the ensuing inflammatory response.
Gay-Crosier
F
F
Department of Medicine, Hôpital Cantonal Universitaire, Geneva, Switzerland.
Polla
L L
LL
Tschopp
J
J
Schifferli
J A
JA
D004396:Coloring Agents / Q000627:therapeutic use; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D003185:Complement C8 / Q000378:metabolism; D003186:Complement C9 / Q000378:metabolism; D003170:Complement Pathway, Alternative; D006391:Hemangioma / Q000276:immunology / Q000532:radiotherapy*; D006801:Humans; D053685:Laser Therapy; D012867:Skin / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000276:immunology / Q000532:radiotherapy*
D004396:Coloring Agents; D003176:Complement C3; D003185:Complement C8; D003186:Complement C9